In 2023, Gilead sold $1.5 billion of one CAR-T therapy, Yescarta. Novartis, which launched the rival Kymriah first, booked $508 million. The gap between those two numbers says a lot about how the first cell therapies for cancer turned out.
Gilead’s year
Gilead reported that its cell therapy sales rose 28% to $1.9 billion for the full year 2023. Yescarta, up 29%, carried most of that, helped by demand from large B-cell lymphoma patients. Its sister product Tecartus grew 24% to $370 million, with relapsed or refractory ALL and mantle cell lymphoma driving the increase.
The fourth quarter looked steady. Cell therapy brought in $466 million, up 11%, and Yescarta alone made $368 million, a 9% gain that the company put down mainly to demand outside the United States. During the year Gilead also won an FDA label update that added survival results from the phase 3 trial known as ZUMA-7, and shortened the expected US turnaround for Yescarta by two days, to 14.
Kymriah slipping
Kymriah has gone the other way. Guidechem, an industry data site, traced its sales from a peak of $587 million in 2021 to $536 million in 2022, then $508 million in 2023, a drop of 5.2%. That was the third year of continuous decline. It fell again in 2024, to $443 million.
Why first place did not last
Gilead paid close to $12 billion for Kite in 2017, and Yescarta reached the market only six weeks after Novartis’s therapy. Being first has been worth less than expected, pharmaphorum argued in December 2024. Manufacturing capacity was hard to build, rivals moved in, and the early leaders lost ground.
The pressure showed up in Gilead’s own third-quarter numbers for 2024. Yescarta made $387 million, 1% lower than a year earlier, and Tecartus grew only 2%. Kite executive Cindy Perettie told investors the stall came from two sources, about 50% each: other CAR-Ts with the same indications and expanded capacity, and bispecific antibodies treating the same patients.
Novartis reported Kymriah net sales of $102 million in the same quarter, down 18%. The therapy did not show a benefit in the second-line setting for aggressive B-cell non-Hodgkin lymphoma, where rivals did, and Novartis also drew an FDA Form 483 over its production process.
The challengers
By the end of 2024 the US FDA had approved seven CAR-T products. Bristol Myers Squibb’s Breyanzi took in $747 million that year, up 105%. Carvykti, the BCMA-directed therapy that Johnson & Johnson sells with Legend Biotech, reached $963 million, up 92.7%. Abecma, BMS’s other product, slid to $406 million, a fall of about 14%.
More than 200 CAR-T assets sit in the development pipeline.
Sources
- Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results
- 2024 CAR-T Sales Performance: Kymriah, Yescarta, Breyanzi & More | Guidechem
- Can CAR-T first movers keep pace in a rapidly evolving market? | pharmaphorum





